Metrics to compare | 688302 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship688302PeersSector | |
|---|---|---|---|---|
P/E Ratio | −21.9x | 11.1x | −0.3x | |
PEG Ratio | −1.28 | 0.21 | 0.00 | |
Price/Book | 2.9x | 3.1x | 2.6x | |
Price / LTM Sales | 46.4x | 5.7x | 3.0x | |
Upside (Analyst Target) | - | 37.9% | 54.6% | |
Fair Value Upside | Unlock | 1.2% | 8.6% | Unlock |
Hinova Pharmaceuticals Inc., a clinical-stage pharmaceutical company, develops and produces therapeutics for cancers and metabolic syndromes. Its core product is Hainaan, a deuterium enzalutamide soft capsules for the treatment of prostate cancer; it also develops drugs based on proteolysis targeting chimera and deuteration technology. The company’s products pipeline includes HP518, a PROTAC molecule targeting advanced prostate cancer; HP537, a small-molecule anti-tumor drug; HP515, an orally administered which improves liver and blood biochemical indicators; HP570, an orally administered molecular gel degrader targeting VAV1; and HC-X049, a small molecule project with STAT6 target layout. Hinova Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in Chengdu, China.